Results 191 to 200 of about 20,829 (242)

Drug Interactions With Excessive Daytime Sleepiness Treatments. [PDF]

J Pharm Technol
Thomas SV, Malesker MA, Hilleman DE, Dewan NA.   +3 more
europepmc   +1 more source

Advancing Narcolepsy Advocacy: Bridging Patient Narratives and Systemic Change. [PDF]

Nat Sci Sleep
BaHammam AS, Jesteadt L, Dhafar H, Sharafkhaneh A.   +3 more
europepmc   +1 more source

Impact of neuromodulation on excessive daytime sleepiness: a narrative review. [PDF]

Front Psychiatry
Li M, Feng L, Pan W, Zhang X, Du X, Li Z.   +5 more
europepmc   +1 more source

REM Density, Leg Movements, and REM Sleep without Atonia: Differentiating Type 1 from Type 2 Narcolepsy Through Polysomnographic Analysis, a Preliminary Study. [PDF]

Nat Sci Sleep
Xu J, Zhao W, Yan Z, Lu S, Zhang Y, Zang K, Tang J, Huang W.   +7 more
europepmc   +1 more source

Impact of Age at Narcolepsy Onset on Sleep-Onset REM Periods in the Multiple Sleep Latency Test. [PDF]

J Clin Med
Sunwoo JS, Ji KH, Kim D, Kim KM, Choi YH, Cho JW, Kim H, Lee W, Jung YJ, Koo DL, Im HJ, Yang KI.   +11 more
europepmc   +1 more source

Effects of Oveporexton, an Orexin Receptor 2-Selective Agonist, on Cognition in Narcolepsy Type 1: A Secondary Analysis of a Randomized Clinical Trial.

JAMA Neurol
Lammers GJ, Plazzi G, Mignot E, Pizza F, Dauvilliers Y, Barateau L, Maruff P, Scammell TE, Latzman RD, Naylor M, Olsson T, Stukalin E, Tanaka S, Volfson D, Khachadourian V, Harel BT.   +15 more
europepmc   +1 more source